Multi4 Medical

Based in Sweden, Multi4 Medical specializes in innovative surgical technology, particularly an endoscopic instrument designed for the efficient treatment of urinary bladder cancer, enhancing patient care and operational efficiency in healthcare settings. Multi4 Medical focuses on developing advanced surgical instruments for bladder cancer treatment. Founded in 2017 in Jonkoping, Sweden, the company has been involved in one funding round, raising a total of EUR 2. 6 million.

The most recent funding round occurred in April 2026, with a capital injection aimed at advancing technology development and clinical validation. Details on the founder's history and previous ventures are not available. Multi4's core product is a groundbreaking endoscopic instrument designed for the treatment of urinary bladder cancer. This innovative technology operates through a small working channel of an endoscope, allowing for an automated, human-centric approach to cancer treatment.

The Multi4 instrument integrates multiple functions into one device, enabling the application of local anesthesia, resection of tissue samples, automatic transport of those samples, and destruction of cancerous tissue or cessation of bleeding—all performed in a single outpatient visit. This reduces the need for traditional, labor-intensive surgical procedures, significantly enhancing patient experience and reducing healthcare costs. The company primarily targets hospitals, outpatient clinics, and urology departments across Europe and the United States, where bladder cancer treatment is prevalent, aiming to address a substantial market need for effective and efficient cancer care solutions. Multi4 generates revenue through the sale of its single-use endoscopic instruments and associated services to healthcare providers, including hospitals and outpatient clinics.

The business model is structured around direct sales, with clients purchasing the Multi4 instrument for immediate use in bladder cancer procedures, thereby eliminating lengthy hospital stays and reducing treatment costs. Multi4’s offering is positioned as a cost-effective alternative to traditional bladder cancer treatments, which are often burdened with high per-patient lifetime costs. By streamlining the treatment process and reducing operational overhead, Multi4 aims to provide value to its clients while improving patient outcomes. The detailed pricing structure for the Multi4 instrument is expected to reflect the significant savings in time and resources compared to conventional surgical methods, positioning it as a compelling choice in the oncology medical device market.

In April 2026, Multi4 Medical raised EUR 2. 6 million in venture funding from individual and other unspecified investors. The company plans to utilize this funding to advance technology development, validation, and prepare for wider clinical adoption. Moving forward, Multi4 aims to design and launch new products tailored for bladder cancer treatment, with specific timelines yet to be announced.

Additionally, there are strategic plans to expand into new markets, particularly targeting regions outside of Europe and the United States, to broaden its reach and meet the growing demand for effective cancer treatment solutions.